Clinical Images: Imaging Manifestations of Orbital Neurofibromatosis Type 1

REFERENCES

1. ↵
   1. Friedman JM.

   Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999 3 26; 89 1: 1- 6. pmid:10469430

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Shen MH,
   2. Harper PS,
   3. Upadhyaya M.

   Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet. 1996 1; 33 1: 2- 17. pmid:8825042

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Crow FW.

   A clinical, pathological, and genetic study of multiple neurofibromatosis. Springfield, IL: Thomas; 1956.
4. ↵
   1. Rasmussen SA,
   2. Friedman JM.

   NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000 1 1; 151 1: 33- 40. pmid:10625171

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Easton DF,
   2. Ponder MA,
   3. Huson SM,
   4. Ponder BA.

   An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993 8; 53 2: 305- 313. pmid:8328449

   OpenUrlPubMedWeb of Science
6. ↵
   1. DeBella K,
   2. Szudek J,
   3. Friedman JM.

   Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000 3; 105 3 Pt 1: 608- 614. pmid:10699117

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Prada CE,
   2. Rangwala FA,
   3. Martin LJ,
   4. et al.

   Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012 3; 160 3: 461- 467. doi: 10.1016/j.jpeds.2011.08.051. pmid:21996156

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Plotkin SR,
   2. Bredella MA,
   3. Cai W,
   4. et al.

   Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7 4: e35711 doi: 10.1371/journal.pone.0035711. pmid:22558206

   OpenUrlCrossRefPubMed
9. ↵
   1. Staser K,
   2. Yang FC,
   3. Clapp DW.

   Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol. 2012; 7: 469- 495. doi: 10.1146/annurev-pathol-011811-132441. pmid:22077553

   OpenUrlCrossRefPubMed
10. ↵
    1. Tailor TD,
    2. Gupta D,
    3. Dalley RW,
    4. Keene CD,
    5. Anzai Y.

    Orbital neoplasms in adults: clinical, radiologic, and pathologic review. Radiographics. 2013 10; 33 6: 1739- 1758. doi: 10.1148/rg.336135502. pmid:24108560

    OpenUrlCrossRefPubMed
11. ↵
    1. Jacquemin C,
    2. Bosley TM,
    3. Liu D,
    4. Svedberg H,
    5. Buhaliqa A.

    Reassessment of sphenoid dysplasia associated with neurofibromatosis type 1. AJNR Am J Neuroradiol. 2002 4; 23 4: 644- 648. pmid:11950659

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Smith M,
    2. Castillo M.

    Imaging and differential diagnosis of the large eye. Radiographics. 1994 7; 14 4: 721- 728. pmid:7938763

    OpenUrlPubMed
13. ↵
    1. Billiet T,
    2. Mädler B,
    3. D'Arco F,
    4. et al.

    Characterizing the microstructural basis of “unidentified bright objects” in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis. Neuroimage Clin. 2014 4 13; 4: 649- 658. doi: 10.1016/j.nicl.2014.04.005. pmid:24936416

    OpenUrlCrossRefPubMed
14. ↵
    1. Hegde AN,
    2. Mohan S,
    3. Lath N,
    4. Lim CC.

    Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. Radiographics. 2011 Jan-Feb; 31 1: 5- 30. doi: 10.1148/rg.311105041. pmid:21257930

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. North K,
    2. Joy P,
    3. Yuille D,
    4. et al.

    Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology. 1994 5; 44 5: 878- 883. pmid:8190291

    OpenUrlCrossRefPubMed
16. 1. Denckla MB,
    2. Hofman K,
    3. Mazzocco MM,
    4. et al.

    Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet. 1996 2 16; 67 1: 98- 102. pmid:8678124

    OpenUrlCrossRefPubMedWeb of Science
17. 1. Goh WH,
    2. Khong PL,
    3. Leung CS,
    4. Wong VC.

    T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. J Child Neurol. 2004 11; 19 11: 853- 858. pmid:15658789

    OpenUrlPubMed
18. ↵
    1. Moore BD,
    2. Slopis JM,
    3. Schomer D,
    4. Jackson EF,
    5. Levy BM.

    Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology. 1996 6; 46 6: 1660- 1668. pmid:8649566

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Hyman SL,
    2. Gill DS,
    3. Shores EA,
    4. Steinberg A,
    5. North KN.

    T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. J Neurol Neurosurg Psychiatry. 2007 10; 78 10: 1088- 1091. pmid:17299016

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Avery RA,
    2. Fisher MJ,
    3. Liu GT.

    Optic pathway gliomas. J Neuroophthalmol. 2011 9; 31 3: 269- 278. doi: 10.1097/WNO.0b013e31822aef82. pmid:21857190

    OpenUrlCrossRefPubMed
21. ↵
    1. Blazo MA,
    2. Lewis RA,
    3. Chintagumpala MM,
    4. Frazier M,
    5. McCluggage C,
    6. Plon SE.

    Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A. 2004 6 15; 127A 3: 224- 229. pmid:15150770

    OpenUrlPubMed
22. ↵
    1. Gutmann DH,
    2. Rasmussen SA,
    3. Wolkenstein P,
    4. et al.

    Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology. 2002 9 10; 59 5: 759- 761. pmid:12221173

    OpenUrlAbstract/FREE Full Text
23. ↵
    1. Gerber PA,
    2. Antal AS,
    3. Neumann NJ,
    4. et al.

    Neurofibromatosis. Eur J Med Res. 2009 3 17; 14 3: 102- 105. pmid:19380279

    OpenUrlPubMedWeb of Science